In addition, with the recent development of blood biomarkers that are sensitive to onset of amyloid and tau abnormalities (e.g., (9–11)), blood biomarkers may be useful clinical trials outcomes in amyloid clearing trials.(12–14). This evidence concerns the gene MAPT and amyloidosis.